Earnings summaries and quarterly performance for Nkarta.
Executive leadership at Nkarta.
Board of directors at Nkarta.
Research analysts covering Nkarta.
Recent press releases and 8-K filings for NKTX.
Nkarta Provides Update on I&I Program, Enrollment, and Financial Runway
NKTX
Guidance Update
New Projects/Investments
- Nkarta (NKTX) has delayed the I&I data readout from Q4 2025 to next year (2026) to present a more robust dataset using the Flu/Cy lymphodepletion regimen, which has resulted in complete B-cell depletion in all treated patients.
- The Ntrust program has experienced a significantly improved pace of enrollment, leading to dose escalation to the second cohort, with the highest dose cohort anticipated in January. This acceleration is due to the adoption of the Flu/Cy regimen and a protocol amendment enabling indication-agnostic dose escalation and faster patient dosing.
- The FDA has provided guidance that the expansion phase of the Ntrust program could be pivotal, contingent on the dose escalation data.
- Nkarta reported a cash balance of approximately $315 million at the end of Q3 2025, extending its financial runway into 2029 and potentially covering pivotal Phase 2 studies.
Dec 4, 2025, 3:50 PM
Nkarta Delays I&I Data Readout to 2026, Reports Improved Enrollment and Extended Cash Runway
NKTX
Guidance Update
New Projects/Investments
- Nkarta (NKTX) has delayed the readout of its I&I data from the current quarter to next year (2026) to present a more robust dataset using the Flu/Cy lymphodepletion regimen, which has shown complete B-cell depletion in treated patients.
- The company has experienced a significantly improved pace of enrollment for its Ntrust program, dose-escalating to the second cohort and anticipating the highest dose cohort in January.
- Operational efficiencies, including combined DSMB and integrated safety data, allow for indication-agnostic dose escalation and faster patient dosing by eliminating a 30-day stagger. The FDA has also indicated that the expansion phase could be pivotal.
- Nkarta ended the third quarter with approximately $315 million in cash, providing a runway into 2029, which contemplates potential pivotal phase two studies.
Dec 4, 2025, 3:50 PM
Nkarta Provides Update on NKX019 Clinical Development and Autoimmune Disease Programs
NKTX
New Projects/Investments
Guidance Update
- Nkarta is advancing its NKX019 program for autoimmune diseases, noting that all patients treated with fludarabine and cyclophosphamide (fluci) plus their cells have shown deep B cell depletion at any dose level.
- The company is currently enrolling patients at a 2 billion cells per dose level, administered three times, and has the ability to further escalate doses.
- Nkarta highlights the safety profile of NK cells, with little to no cytokine release syndrome (CRS) or neurotoxicities observed across various NK cell data sets, including their own and competitor RuYi's.
- Enrollment has seen an "incredible uptick" following protocol amendments, including the shift to fluci and changes to patient staggering, and the company has cash into 2029.
- A robust and meaningful data set from the fluci-treated cohorts, including B cell depletion, reset data, and clinical outcomes, is expected to be presented sometime next year.
Nov 13, 2025, 10:00 PM
Nkarta Provides Clinical and Financial Update at Stifel Conference
NKTX
Guidance Update
New Projects/Investments
- Nkarta reported over $300 million in cash as of the end of the third quarter (Q3 2025), providing a cash runway into 2029.
- The company has harmonized its two Entrust trials (Entrust 1 for lupus nephritis and primary membranous nephropathy, and Entrust 2 for a basket study including systemic sclerosis, ANCA-associated vasculitis, and myositis). This FDA-approved change streamlines dose escalation by allowing multiple patients to be dosed across all indications after a 14-day sentinel patient observation period, significantly accelerating enrollment.
- Nkarta switched its lymphodepletion regimen to fludarabine and cyclophosphamide (flu/cy), which has resulted in deep B-cell depletion and enhanced patient enrollment in its Phase I clinical trials.
- Nkarta anticipates providing an update on efficacy data across multiple indications in 2026. The company also has regulatory alignment with the FDA regarding the potential for expansion cohorts to be pivotal after dose escalation, similar to other cell therapy companies in the autoimmune space.
Nov 12, 2025, 3:40 PM
Nkarta Reports Third Quarter 2025 Financial Results and NKX019 Clinical Program Update
NKTX
Earnings
Guidance Update
New Projects/Investments
- Nkarta, Inc. reported a net loss of $21.7 million, or $0.29 per basic and diluted share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held a cash balance of $316.5 million, including cash, cash equivalents, and investments, which is expected to fund operations into 2029.
- Research and development expenses were $20.2 million for the third quarter of 2025.
- Enrollment is now underway in the second dose-escalation cohort for the NKX019 clinical program in autoimmune diseases, with initial data expected to be presented at a medical conference in 2026.
Nov 10, 2025, 9:13 PM
NKGen Biotech Clarifies OTC Expert Market Trading Status and Stock Price Display
NKTX
Delisting/Listing Issues
- NKGen Biotech (OTC: NKGN) clarified that the $0.00 common stock price displayed on certain financial websites is due to limitations on public quote dissemination for securities traded on the OTC Expert Market, not a change in the company's underlying fundamentals.
- The company's shares were moved to the OTC Expert Market on or about July 17, 2025, because it failed to meet the requirement to stay current in its filings under the Securities Exchange Act of 1934.
- NKGen's common stock is not delisted and remains tradable; however, real-time price quotes are currently only accessible to broker-dealers and institutional investors.
- To regain compliance, NKGen filed its Form 10-K for the year ended December 31, 2024, on October 8, 2025, and is now focused on completing and filing its Form 10-Qs for the quarters ended March 31, June 30, and September 30, 2025.
Oct 9, 2025, 12:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more